Is Valeant Pharmaceuticals Intl Inc. a Buy on Recent Acquisition News?

Buying Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) on its acquisition news is a smart investment because often when it buys new companies, its value soars.

| More on:
The Motley Fool

It never seems to end for Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX). The Wall Street Journal reported yesterday that Valeant would be acquiring Sprout Pharmaceuticals Inc., the maker of the controversial “female Viagra,” Addyi. Only a few days prior, Sprout had gained FDA approval to sell the drug in the United States.

As is typical with Valeant, it waited until the product was right at the end of its development before it reached out and made its $1 billion bid. The reason this acquisition is so interesting is because of the potential this drug has around the world. First and foremost, this is the first product that takes Valeant into the women’s health product market. This is a big move for the company because it has a global supply chain, but it wasn’t in that particular market.

Second, because it is the first drug of its kind, it doesn’t have to worry about competitors. Consider when Pfizer launched Viagra. Almost immediately after, doctors were prescribing it at a rate of 10,000 a day. Now, I’m not suggesting that this will happen with Addyi because this is targeted towards premenopausal women, but there is certainly a market for it. And with Valeant holding the only pill available, it has the potential to be very successful.

Because of this, I believe that in the long term, Valeant will generate much more than what it paid for the company. More importantly, now that it is entering the women’s health product market, I anticipate even more acquisitions in this sector. This is good because Valeant is not like many other pharmaceutical companies.

It’s a platform company

Bill Ackman, the hedge fund manager, has often said that Valeant is a unique kind of company. He calls it a platform company, similar to Berkshire Hathaway Inc. Berkshire doesn’t launch any unique products and for the most part, Valeant doesn’t have an organic pipeline of products either. Instead, the way that it gains value is through acquisitions.

Ackman believes that portfolio companies are consistently undervalued because the markets aren’t as fast as the acquisition. Consider this: right before Bausch & Lomb was acquired, Valeant traded at $74 per share. After the announcement, it jumped to $95. Before it bought Salix, it was trading at $217. After the announcement, it jumped to $250.

If we look at Valeant under the classic lens of value investing, this company is an awful investment. Its P/E is outrageous, it has a significant amount of debt, and it doesn’t bring any organic products to market. However, if we view it as a platform company that acquires other companies for value, I can suddenly start seeing good, long-term potential on pharmaceutical acquisitions.

Because of this, I say Valeant is worth the investment. And with how things are going around the world, you might be able to find some valuable shares at a decreased price as everyone rushes away from the market.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Jacob Donnelly has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Berkshire Hathaway and Valeant Pharmaceuticals.

More on Investing

Senior Man Sitting On Sofa At Home With Pet Labrador Dog
Dividend Stocks

RRSP Investors: Don’t Miss Out on This Contribution Hack!

This hack has so many benefits for you -- not just when you put it in your RRSP but for…

Read more »

edit Sale sign, value, discount
Stocks for Beginners

These 3 Growth Stocks Are on Sale and Set to Surge

Some growth stocks are on sale right now that offer massive long-term potential for investors. Here's a trio to consider…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Young woman sat at laptop by a window
Dividend Stocks

3 Dividend Stocks Everyone Should Own for the Long Haul

For investors looking for top-tier dividend stocks to buy and hold for the long term, here are three of my…

Read more »

A red umbrella stands higher than a crowd of black umbrellas.
Dividend Stocks

Passive Income: 2 Safe Dividend Stocks to Own for the Next 10 Years

Dividend stocks such as Manulife and Fortis can help you generate a stable and recurring passive-income stream.

Read more »

Payday ringed on a calendar
Dividend Stocks

3 Dividend Stocks That Pay Me More Than $54.57 Per Month

These three dividend stocks have done me well over the years, so let's look at how much I've gotten in…

Read more »

Golden crown on a red velvet background
Dividend Stocks

Dividend Royalty: 3 Fabulous Stocks to Buy Now for Decades of Passive Income

Rogers Communications stock and Canadian Natural Resources stock could pay you dividends for decades to come.

Read more »

stock analysis
Investing

“GARP” Investing: 3 Can’t-Miss Stocks to Buy Now

goeasy (TSX:GSY) and other low-cost growth stocks could make your portfolio a market beater over the long run!

Read more »